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1. Introduction 
1.1 Th cell development 
Regulation of T helper (Th) cell differentiation and proliferation depends on which 
cytokines are present in the microenvironment of a naïve Th cell. Induction of specific 
transcription factors results in programming of the naïve Th0 cell into one of several subsets. 
Currently there are four well characterized Th cell subsets, namely Th1, Th2, Th17, and the T 
regulatory (Treg) cells (Figure 1). In this chapter we will be focusing on the Th1, Th17, and 
Treg cell populations. However, at this point it is also worth mentioning the relatively 
newly described Th9 and follicular (Tfh) cell subsets. Here we briefly discuss the 
differentiation pathways taken by a Th0 cell that ultimately results in the formation of these 
different subsets.  
Since the early 1980’s, the Th1/Th2 paradigm has been well-studied. Th1 cells are known for 
expression of the signature cytokine IFN-Ǆ and resulting anti-viral activities. The necessary 
driving cytokine for these cells is IL-12 in conjunction with the Th1-specific transcription 
factor T-bet (Hsieh, Macatonia et al., 1993; Seder, Gazzinelli et al., 1993;Szabo, Sullivan et al., 
2002). IL-27, related to IL-12, has been recently shown to play a role in the induction of Th1 
cells, while also actively repressing development of other subsets. On the other hand, Th2 
cells are largely recognized to support humoral immunity and are induced by the presence 
of IL-4 and resulting activation of the STAT6 transcription factor(Kaplan, Schindler et al., 
1996;Kurata, Lee et al., 1999). Equally important is the activation of the GATA binding 
protein 3 (GATA-3), the main regular of Th2 development (Pai, Truitt et al., 2004;Zhu, Min 
et al., 2004). The newly defined Th17 cells have been implicated in a number of 
inflammatory disorders and are recognized as key Th cells that trigger massive 
proinflammatory responses. They are characterized by production of IL-17 and 
differentiation of these cells requires both tumor growth factor (TGF)-β and IL-6 which act 
together to promote development of the Th17 subset (Bettelli, Carrier et al., 2006; Mangan, 
Harrington et al., 2006). Additionally important to the generation of these cells is IL-23, 
which functions to aid in the development and proliferation of Th17 cells. The key 
transcription factors required belong to the retinoic acid-related orphan receptors (ROR) 
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family; both ROR-ǂ and RORγt have been shown to be critical to Th17 development (Yang, 
Pappu et al., 2008). The Treg cell subset is crucial to the regulation of immune responses as 
these cells play a suppressive role, mainly via the expression of the anti-inflammatory 
cytokine IL-10. These cell subsets are unique from the other subsets as they can be formed 
either in the thymus (known as “naturally” occurring Tregs or nTreg) or as a result of TGF-β 
stimulation and T cell receptor (TCR) triggering (known as “inducible” Tregs or 
iTreg)(Murai, Krause et al., 2010). The main transcription factor for the development of these 
cells is Foxp3 which is only expressed in Treg cells (Zheng & Rudensky, 2007). Th9 cells 
have been recently identified as IL-21-dependent CD4 T cells producing IL-9, although a key 
function has yet to be identified for these cells, it appears that they may be involved in 
inflammation and allergy (Xing, Wu et al., 2011; Ma, Tangye et al., 2010; Wong, Ye et al., 
2010). The Tfh cells are newly defined to be efficient producers of IL-10 and IL-21 (Suto, 
Kashiwakuma et al., 2008; Crotty, 2011). These cells generally express high levels of CXCR5 
and are responsible for providing support for B cells (Crotty, 2011). Key to the 
differentiation of these cells, are IL-6 and IL-21 which mediate the induction of the 
transcription factor Bcl-6 (Nurieva, Chung et al., 2009).  
 
 
Fig. 1. CD4 T cell Differentiation Pathways: Naïve T cells (Th0) cells can differentiate into 
different subsets of T cells depending on the cytokine(s) present in the cell environment. 
Shown in this diagram are the cytokines required for each cell type, the transcription factors 
required for each cell type (in italics), and the main cytokine(s) produced by each cell type 
(in bold). 
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The IL-12 family of cytokines is composed of IL-12, IL-23, and IL-27, with each of these 
cytokines playing a different role in Th cell development. Proper regulation of the 
development and differentiation of CD4 T cells is critical to an effective immune response. 
As these cells are the main target of HIV infection, the resulting loss and imbalance of the Th 
cell subsets are a hallmark of HIV and AIDS. The remainder of this chapter will be devoted 
to a discussion of the impact of HIV infection on the function and expression of the IL-12 
cytokine family members as it relates to Th cell differentiation and function with a focus on 
how Th1, Th17, and Treg CD4 T cell subsets are affected. 
2. IL-12 and HIV infection 
IL-12 is critically involved in generating cell-mediated immune responses to infectious agents, 
including HIV. Biologically active IL-12p70, a dimer of IL-12p35 and IL-12p40, is secreted by 
activated monocytes, macrophages, and dendritic cells. IL-12 expression drives the 
production and development of the Th1 subset of T cells, and is responsible for the 
induction of IFN- expression from these cells(Alber, Al-Robaiy et al., 2006).  
IL-12 production is impaired in HIV-infected individuals and in cells infected in vitro with 
HIV (Chehimi, Starr et al., 1999; Daftarian, Diaz-Mitoma et al., 1995; Boucher, Parato et al., 
2010;Buisson, Benlahrech et al., 2009). In terms of IL-12 receptor chain expression (IL-12R1 
and IL-12R2), one study reported that resting peripheral blood mononuclear cells (PBMC) 
from HIV positive patients and HIV negative controls did not express IL-12Rǃ1 or IL-12Rǃ2 
chains on their cell surface (Jones, Young et al., 2003). Upon examination of mRNA levels, 
the group found that levels of both receptor subunits were markedly reduced in HIV 
positive patients compared to HIV negative controls. Culture of activated cells with IL-12 
resulted in upregulation of the IL-12R2 chain suggesting that treatment with IL-12 may 
serve to recapitulate IL-12R levels and thus IL-12 responses (Jones, Young et al., 2003). In 
contrast, a recent study demonstrated that unstimulated CD4 T cells from HIV-1 positive 
patients expressed a two-fold increase of IL-12Rǃ1 subunit compared with cells from HIV-1 
negative controls (de Arquer, Pena et al., 2007). Similar to Jones et al (2003), this group 
found that stimulation of the CD4 T cells with IL-12 resulted in the enhancement of IL-
12R2. Together these two findings illustrate the potential importance of restoring IL-12 
mediated responses, particularly in view of the role of IL-12 in Th1 cell differentiation and 
IFN- production.  
The above observations suggest that although the virus inhibits IL-12 production, the 
immune cells attempt to bolster responses via upregulation of IL-12 receptor levels, which 
leads to speculation that treatment with IL-12 may be beneficial to patients. In in vitro 
models using T cells isolated from HIV patients, enhanced immune responses are observed 
upon treatment of these cells with recombinant IL-12 (Landay, Clerici et al., 1996). Vectors 
expressing IL-12 have also been used successfully in candidate vaccines in animal models 
(Chong, Egan et al., 2007; Boyer, Robinson,et al., 2005; Egan, Chong et al., 2005;Hirao, Wu et 
al., 2008). IL-12 is important for the priming of antigen-specific T cells, as demonstrated by a 
study using IL-12 deficient mice. Mice were immunized with HIV gp120 cDNA vectors and 
the cytotoxic T cell response in IL-12 deficient mice was significantly lower compared to 
wild type mice. Furthermore, reconstitution of IL-12 in the deficient mice was able to restore 
T cell responsiveness (Gupta et al., 2008). However, toxicity of IL-12 as a treatment option is 
a concern. Therefore, use of other cytokines which may have less toxicity, such as IL-23 or 
IL-27 is of interest. Additionally, treatment with anti-receptor or anti-cytokine antibodies to 
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IL-12 and IL-23 has proven useful in treatment of autoimmune diseases(Ding, Xu et al., 
2008;Elson, Cong et al., 2007;Gottlieb, Cooper et al., 2007;Krueger, Langley et al., 2007). 
Treatment with recombinant IL-27 has also proven useful in an in vitro model of arthritis 
(Niedbala, Cai et al., 2008). Together, these points indicate alternative recombinant cytokine 
treatments could be applied in emerging HIV therapeutics. 
3. IL-27 and HIV infection 
IL-27 was first discovered in 2002 by Pflanz et al. as a novel member of the IL-12 family of 
cytokines (Pflanz, Timans et al., 2002). This family is comprised of molecules sharing subunits 
and receptor chain components; therefore, IL-27 and IL-12 have similar functions. IL-27 
engages a heterodimeric receptor composed of gp130 and WSX-1 (Pflanz, Hibbert et al., 2004). 
Numerous immune cells respond to IL-27, as the IL-27 receptor can be found on endothelial 
cells, mast cells, activated B cells, monocytes, Langerhans cells, activated DCs, and polarized 
Th cells (Larousserie, Charlot et al., 2006; Lucas, Ghilardi et al., 2003; Pflanz, Hibbert et al., 
2004;Ruckerl, Hessmann et al., 2006;Wirtz, Tubbe et al., 2006). Functionally, IL-27 exhibits pro- 
and anti-inflammatory properties and, thus, IL-27 can be regarded as an immunomodulatory 
cytokine. Recent evidence has indicated a role for IL-27 in the regulation of 
monocyte/macrophage function (Guzzo, Che Mat et al., 2010; Kalliolias & Ivashkiv, 2008), in 
addition to its well-characterized functions in T cells. IL-27, predominantly produced by 
activated monocytes and dendritic cells, can bridge innate and adaptive immunity by playing 
a key role in the activation of naïve T cells and differentiation to Th1 cells.  
A role for IL-27 in the control of HIV replication was first described in 2007 (Fakruddin, 
Lempicki et al., 2007). This study evaluated the effects of HPV-VLPs (Human Papilloma 
Virus - Virus-Like Particles) on HIV-1 replication in PBMC, CD4 + T cells, and macrophages. 
Using the p24 antigen capture assay to assess viral replication, this study showed treatment 
with HPV-VLPs could suppress replication of both X4 and R5 strains of HIV-1. This 
suppression was independent of any effect on cell surface expression of CD4, CXCR4, or 
CCR5, as analyzed by surface staining and flow cytometry. Upon observing the anti-HIV 
effect of VLP treatment, the authors went on to perform DNA microarray analysis to look at 
gene expression profiles in PBMC and macrophages treated with VLPs. The authors noticed 
induction of interferon (IFN), IFN-stimulated genes (ISIGs),  cytokines like IL-10, IP-10, IL-
15, and most notably, IL-27. Thus, the anti-HIV effects seen with VLP treatment resulted 
from the release of suppressive factors following treatment of cells with HPV-VLPs. VLP-
induced IL-27 expression and production in PBMC and macrophages was further confirmed 
and quantified using RT-PCR and ELISA, respectively. To tease out the specific role of IL-27 
in suppression of HIV replication, the authors immunodepleted IL-27 from VLP-treated cell 
supernatants, and saw a significant reduction in the inhibition of HIV replication, indicating 
IL-27 secretion may be one factor contributing to the suppressive effects seen upon VLP 
treatment of HIV-infected cells. To confirm the direct effect of IL-27 on HIV replication, this 
study went on to treat cells with a recombinant IL-27 (rIL-27) dose response and showed 
increasing suppression of HIV replication in the presence of increasing rIL-27 doses. 
Furthermore, to determine the specificity of IL-27-mediated inhibition of HIV replication, 
the authors performed real-time RT-PCR to examine transcription of HIV RNA in the 
presence of IL-27. Results indicated a 60 – 80% decrease in HIV transcription in the presence 
of IL-27. Lastly, the authors performed DNA microarray analysis on PHA-stimulated CD4 + 
T cells in the presence or absence of IL-27 to compare gene induction profiles. Cells cultured 
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in the presence of IL-27 showed significant upregulation of antiviral genes, including ISIGs, 
myxovirus resistance protein, and 2’-5’-oligoadenylate synthetase. 
Shortly after the initial discovery of the IL-27 anti-HIV functions, the same research group 
examined the mechanisms of IL-27 antiviral activity compared to those of IFN-, another 
key cytokine also known to inhibit HIV replication. In this study the activity and gene 
expression profiles of IL-27 and IFN- were compared in human CD4 + T cells and 
macrophages (Imamichi, Yang et al., 2008). The authors performed a neutralization assay to 
define the role of IFN in IL-27-mediated inhibition of HIV replication. HIV-infected CD4 T 
cells and macrophages were treated with IL-27 in the presence/absence of an antibody 
cocktail containing neutralizing antibodies to each IFN. The antibody treatment did not 
affect HIV inhibition by IL-27, indicating that IFN is not an intermediate in the inhibition of 
HIV replication by IL-27. Of additional note, IL-27, like IFN-, preferentially inhibited HIV 
replication in macrophages compared to CD4 T cells, as lower doses of these cytokines were 
required to get complete inhibition of HIV replication in macrophages compared to T cells. 
Using DNA microarray analysis, this study went on to compare the gene expression profiles 
of IL-27 and IFN- in CD4 T cells and macrophages. From this experiment it was noted that 
both cytokines induced a similar profile of ISIGs and antiviral genes, with greater antiviral 
gene induction in the macrophages compared to CD4 T cells upon IL-27 stimulation. Of 
particular note, IL-27 significantly upregulated antiviral genes like myxovirus resistance 1 
(MX1), oligoadenylate synthetase 2 (OAS2), and RNA-dependent protein kinase–eukaryotic 
initiation factor 2a kinase (PKR/EIF2AK) by greater than 2-fold in the macrophage cells. 
Furthermore, IL-27 also induced expression of apolipoprotein B messenger RNA-editing 
enzyme-catalytic polypeptide-like 3G (APOBEC3G) in macrophages, but not in CD4 T cells. 
The APOBEC proteins are key host cell-derived protective molecules, acting as anti-HIV 
proteins that function as cytidine deaminases to interfere with viral replication (Romani, 
Engelbrecht et al., 2009). Taken together, these results indicate that IL-27, like IFN-, 
significantly induces multiple IFIGs and APOBEC3G in macrophages, resulting in the 
striking anti-HIV functions of these cytokines. 
Subsequent to the initial studies on IL-27 functions in HIV infection, a separate research group 
set out to determine whether IL-27 directly or indirectly regulated expression of the APOBEC 
family of proteins (Greenwell-Wild, Vazquez et al., 2009). Since it had been previously shown 
that IFN- could regulate expression of APOBEC, clinical trials commenced to explore the 
impact of IFN- treatment on induction of APOBEC expression in the setting of HIV infection 
et (Neumann, Polis et al., 2007). However, the many negative side effects of IFN treatment led 
researchers to consider alternative mechanisms to induce APOBEC expression, in particular, 
mechanisms that minimize IFN toxicities associated with direct administration of this 
cytokine. Greenwell-Wild et al. (2009) showed that IL-27 could be a good alternative, as they 
showed IL-27 can induce APOBEC expression to curb HIV replication. This study attributed 
the anti-viral properties of IL-27 to the intermediary IL-27-induced IFN-, which can then, in 
turn, coordinate anti-viral responses. Interestingly, this study investigated whether other IL-12 
cytokine family members, namely IL-12 and IL-23, could suppress HIV replication. No 
significant reduction in HIV replication was observed with IL-12 or IL-23 treatments, 
indicating that the inhibition of HIV replication was selective to IL-27 in the IL-12 family of 
cytokines. This study went on to examine the kinetics of IL-27-induced APOBEC expression 
and found a 24 hour delay in the induction of expression by real-time PCR, suggestive of an 
intermediary in the induction of APOBEC expression. Since it was previously known that IFN-
 could regulate APOBEC expression, IFN- and IFN- became likely agents for the 
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intermediary molecules mediating IL-27-induced APOBEC expression. Greenwell-Wild et al. 
(2009) went on to show IL-27 can induce expression of both IFN- and –, and that these IFNs 
alone could inhibit HIV replication (p24 assay). Lastly, to confirm that IL-27 induces APOBEC 
expression through IFN, they blocked the IFNreceptor (IFNAR) with neutralizing 
antibody, followed with IL-27 stimulation, and found no induction of APOBEC expression, 
indicating IFN is an intermediate requirement in IL-27-induced APOBEC expression. 
Furthermore, when IFN and IL-27 were added in unison to cell cultures, enhanced inhibition 
of HIV replication was observed, pointing to additional antiviral mechanisms under the 
regulation of these cytokines. Taken together, this study illustrates teamwork between two 
cytokines, IFN and IL-27, in the suppression of HIV. 
So far we have reviewed how IL-27 can suppress HIV replication; however, limited studies 
have described how HIV can affect IL-27. The first study to investigate the impact of HIV 
infection on IL-27 investigated how clinical characteristics such as viral load, hepatitis C 
virus (HCV) co-infection, and CD4 T cell counts were associated with changes in circulating 
levels of IL-27 (Guzzo, Hopman et al., 2010). Guzzo et al. (2010) observed a modest negative 
correlation between IL-27 levels and HIV viral load, suggesting that circulating HIV virus 
may suppress IL-27 expression, a potential pathogenic mechanism for the virus to limit host 
anti-viral responses. Additionally, in this study, when patients were grouped according to 
those receiving HAART therapy and those naïve to HAART, no difference was found in IL-
27 expression, illustrating no impact of HAART on IL-27 expression. Lastly, this study 
investigated if IL-27 expression was associated with changing CD4 T cell counts. A 
consistent trend was observed among patient groups, namely, IL-27 expression peaked with 
moderate declines in CD4 T cell counts (200-350), then decreased in the low CD4 T cell count 
(<200) patients. The study authors hypothesized that the initial boost in IL-27 signified the 
host response to viral insult (declining CD4 T cells), as the host upregulates the anti-HIV 
cytokine as a protective response. However, as HIV disease progresses, dysregulated 
immune responses and increasing viral loads renders the host unable to produce adequate 
IL-27, and the observation of decreased IL-27 with low CD4 T cells counts was observed. 
Overall, this study suggested that HIV viral load, HCV co-infection, and CD4 T cell counts 
are strongly associated with changes in circulating levels IL-27 in the HIV-infected host. This 
research was the first to report how HIV infection might affect expression of IL-27, and to 
date, only one other study has investigated the effect of HIV on IL-27 expression (Palermo, 
Patterson et al., 2011). Palermo et al. (2011) performed alternative AIDS vaccine strategies in 
rhesus macaques followed by viral challenge with adenovirus-expressing HIV-env, SIV-gag, 
or SIV-nef proteins. Following vaccination and viral challenge, global transcriptional 
profiling was performed to characterize any significant alterations in gene expression. At the 
time of peak viremia in the animals, gene expression profiles of the immunized groups were 
different from that of controls. Of particular note was an upregulation of IL-27 expression in 
the immunized group, indicating the protective host response to virus is a boost in the anti-
viral cytokine, IL-27. This study reported significant differences in gene expression of a 
variety of immunological markers between treatment groups, suggesting new potential 
correlates of protection in HIV infection.  
Taking into account the role of IL-27 in driving the differentiation of Th1 cells and keeping 
in mind the ability of IL-27 to inhibit HIV replication, it is clear that further understanding 
of the regulation of IL-27 expression and function during HIV infection is an important area 
of research. It is possible that the use of treatments that upregulate the expression of this 
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cytokine may have a two-pronged beneficial effect: inhibition of virus replication and 
reinstating the Th1 CD4 T cell populations.  
4. IL-23 and HIV infection 
As discussed, the IL-12 family of cytokines regulates CD4 T cell development and immune 
responses. In particular, IL-23 is an IL-12 family member important in regulating the 
differentiation of the proinflammatory, IL-17-producing, Th17 cells. IL-23, a heterodimeric 
cytokine composed of covalently linked IL-12p40 and IL-23p19 subunits was originally 
discovered in 2000 and identified as a member of the IL-12-related cytokine family 
(Oppmann, Lesley et al., 2000). IL-23 is predominantly produced by activated myeloid cells 
such as activated monocytes, antigen-presenting cells, including dendritic cells and 
macrophages, T cells, B cells and endothelial cells (Oppmann, Lesley et al., 2000;Parham, 
Chirica et al., 2002;van Seventer, Nagai et al., 2002). IL-23 shares the IL-12p40 subunit with 
IL-12, and the IL-23-specific subunit, p19, forms a disulphide-linked heterodimer with the 
IL-12p40 subunit(Oppmann, Lesley et al., 2000). The high affinity IL-23 receptor complex is 
comprised of an IL-12Rǃ1 (as found in IL-12 receptor) and a unique IL-23Rǂ subunit 
(Parham, Chirica et al., 2002). As mentioned in the previous section on IL-12, many studies 
have shown the effect of HIV infection on the production of IL-12 and IL-12 receptor 
expression; there is strong evidence suggesting that IL-12 production is impaired in cells 
infected in vitro with HIV and in HIV positive patients (Chehimi, Starr et al., 1994; Marshall, 
Chehimiet al., 1999;Daftarian, Diaz-Mitoma et al., 1995;Boucher, Parato et al., 2010; Buisson, 
Benlahrech et al., 2009). Since IL-12 and IL-23 share the p40 subunit as well as the IL-12R1 
receptor subunit, it is interesting to speculate on the impact of HIV on IL-23 function and the 
involvement of IL-23 in HIV pathogenesis. 
The ability of immune cells to produce IL-23 during HIV infection has not been fully 
studied. Lee and colleagues were the first to demonstrate that spontaneously produced 
IL-23p19 and IFN-Ǆ mRNA from PBMC are reduced in HIV positive patients who 
exhibited increased CD4 T cell counts while on long term HAART (Lee, French, & Price, 
2004). The inability of the cells to produce “normal” levels of these key cytokines may 
compromise the immune response to opportunistic infections. A very recent study 
showed that LPS-induced IL-23 production by monocytes and dendritic cells from HIV 
positive patients was actually increased compared to HIV negative controls (Louis, 
Dutertre et al., 2010). This study included the first longitudinal analysis of IL-23 
production during primary HIV infection. The authors found that the production of IL-23 
was greatly increased and sustained during chronic infection. Interestingly, in response to 
simultaneous LPS and IFN-Ǆ treatment, they also found that IL-23 production, but not IL-
12p70 production correlated strongly with viral loads. This study indicates that HIV 
induces the production of IL-23, and that IL-23 may have an important role in controlling 
viral infection. However, taken together, these studies have conflicting results. In the study 
by Lee et al., mRNA levels of p19 were examined whereas Louis et al. examined secreted 
IL-23, which may partially explain the observed discrepancy. In 2004, a study revealed 
that IL-23 has potent adjuvant effects on induction of epitope-specific cytotoxic T 
lymphocytes (CTLs) (Matsui, Moriya et al., 2004). The authors found that co-
administration of an IL-23 expression plasmid in a prime-boost immunization enhanced 
the induction of Hepatitis C virus (HCV)-specific CTLs in mice. This finding suggests that 
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IL-23 might offer a new prophylactic and therapeutic strategy for vaccine development 
against infectious pathogens.  
To date, the mechanism of how HIV affects the production of IL-23 is still not clear. 
However, a few studies have been reported on the molecular mechanism of the inhibitory 
action of HIV on IL-12, a related cytokine sharing the IL-12p40 subunit and IL-12R1 
receptor subunit with IL-23. An in vitro study showed that HIV infection of myeloid cells 
was able to disrupt MAP kinase activation and transcription factor binding to the IL-12p40 
promoter(Chambers, Parks et al., 2004). This observation may be explained as a direct effect 
of HIV on the IL-12p40 promoter or may occur as a consequence of altered MAP kinase 
activation. Indeed, the authors demonstrated that the phosphorylation of JNK and p38 
MAPK was impaired and the phosphorylation and degradation of IκBǂ was suppressed 
after HIV infection (Chambers, Parks, & Angel, 2004). Another in vitro study found that 
intracellular Nef inhibits LPS-induced IL-12p40 transcription by inhibiting the JNK-
activated NF-κB without affecting AP-1 activity (Ma, Mishra et al., 2009). This result 
suggests that intracellular Nef selectively inhibits NF-B activity (apart from other 
transcription factors, such as AP-1), resulting in the inhibition of IL-12p40 expression. 
Similar studies on the molecular mechanism of IL-23p19 regulation in the context of HIV 
infection have yet to be published. 
It is well known that IL-23 is important for the development of a proinflammatory subset of 
T cells, Th17. Little is known about how HIV modulates the function of IL-23 and how HIV 
affects the main downstream functions of this cytokine in the promotion of Th17 cells. If 
HIV infection decreases IL-23 production, Th17 expansion and activation may be 
downregulated. To date, no study has examined the correlation between IL-23 and the IL-
23/Th17 axis in HIV positive patients. Like IL-23, the roles of Th17 and IL-17 in HIV-
replication and immunopathogenesis are not well understood. In the next section we will 
discuss the impact of HIV infection on Th17 cell regulation.  
5. Th17 cells and HIV infection 
The discovery of the Th17 subset has expanded our understanding of T cell mediated 
immunity, leading to a revision of the classical model of T cell populations. Th17 is a 
proinflammatory T cell population that is involved in host immune defense against 
pathogens not adequately handled by Th1 or Th2 cells. The Th17 subset is termed after its 
main effector proinflammatory cytokine, IL-17. The differentiation of Th17 subset is driven 
by the combination of TGF-ǃ and IL-6 which upregulate the transcription factor RORǄt 
(McGeachy, Chen et al., 2009). Th17 cells mediate inflammation through upregulation of 
chemokine and inflammatory cytokine expression, and recruitment of macrophages and 
neutrophils (Gaffen, Kramer et al., 2006;Korn, Bettelli et al., 2009). The inflammatory 
response is amplified by the presence of all these factors, resulting in a greater inflammation 
than the response from Th1/Th2 cells. Th17 cells have been demonstrated to be specifically 
involved in immunity against Toxoplasma gondii, Candida albicans, Klebsiella pneumoniae and 
Mycobacterium tuberculosis (Conti, Shen et al., 2009; Gaffen, Kramer, Yu, & Shen, 2006; Korn, 
Bettelli, Oukka, & Kuchroo, 2009). However a role for Th17 cells in the regulation of virus 
infection has been a recent focal area of research, particularly in the case of HIV. 
Mucosal transmission of HIV is the main route of virus entry and site of initial virus infection. 
Th17 cells play important roles in the regulation of mucosal immunity, and they are found in 
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high concentration in the lamina propria of the GI tract (Hunt, 2010). Th17 cells prevent 
microbial translocation across mucosal surfaces by enhancing expression of antimicrobial 
peptides and mobilizing neutrophils to infected sites. At the same time, gut-associated 
lymphoid tissue (GALT) is a major reservoir for CD4 T cells, the source of Th17 cells, and a key 
site of HIV replication and CD4 T cell loss (Brenchley, Schacker et al., 2004;Mehandru, Poles et 
al., 2004). Pathogenic SIV as well as HIV infection results in rapid and significant Th17 loss 
from the GALT which would be expected to have deleterious effects on the regulation of 
microbial translocation (Brenchley, Schacker et al., 2004; Raffatellu, Santos et al., 2008). Indeed, 
HIV infection is correlated with increases in microbial translocation and mucosal inflammation 
(Gori, Tincati et al., 2008). This is supported by studies showing that plasma LPS levels, 
considered as an indication of microbial translocation, in HIV infected individuals are 
remarkably higher than uninfected individuals (Jiang, Lederman et al., 2009;d'Ettorre, 
Paiardini et al., 2011). Interestingly, SIV infected rhesus macaques exhibited Th17 depletion in 
ileal mucosa, resulting in a compromised mucosal barrier and susceptibility to Salmonella 
infection compared to that observed in uninfected macaques (Raffatellu, Santos, et al., 2008). 
Furthermore, in the same study, IL-17R deficient mice also had increased systemic 
dissemination of Salmonella from the gut. Together, this suggests that IL-17 deficiency may 
lead to impaired mucosal barrier function. An interesting report on V1 T cells, T cells present 
in mucosal tissues expressing the T cell receptor, demonstrated that HIV positive 
individuals exhibited an expanded population of these cells that produced both IFN-Ǆ and IL-
17 (Fenoglio, Poggi et al., 2009). This is of interest to mucosal immunity and HIV, as circulating 
Vǅ1 T lymphocytes, resident cells in GALT, are increased in HIV-1 infection due to mucosal 
depletion and recirculation (Nilssen, Muller et al., 1996;Fenoglio, Poggi et al., 2009). 
Additionally, Fenoglio et al. (2009) showed that these cells were able to proliferate and 
produce IFN-Ǆ and IL-17 in response to C. albicans and that these cells expressed markers for a 
memory T cell phenotype as well as the Th17 transcription factor RORC. The elevation of this 
subset of T cells in the context of HIV infection may represent a possible mechanism to 
compensate for impaired CD4 T cells, and in particular, that of Th17. 
Studies elucidating the relationship between Th17 cells and HIV infection have yielded 
inconclusive results. The first report that associated HIV with IL-17 showed an increase of 
IL-17 production by CD4 T cells in peripheral blood of HIV patients both in cells left 
untreated or stimulated with PMA/ionomycin (Maek, Buranapraditkun et al., 2007). It was 
later shown that HIV-1 infected children with a plasma viral load of below 50 copies/ml 
(undetectable HIV) had enhanced IL-17 production in contrast to those with detectable HIV, 
which had no observable IL-17 production (Ndhlovu, Chapman et al., 2008). This suggested 
a possible impairment of Th17 cells in patients with detectable HIV levels and decreased IL-
17 levels, and that restoration of Th17 cells could be possible through suppression of 
viremia. In 2008, Macal et al. showed that CD4 T cell restoration (>50%) could be achieved 
regardless of persistent proviral burden and previous HAART (Macal, Sankaran et al., 2008). 
This CD4 T cell restoration was associated with enhanced Th17 CD4 T cell accumulation. 
Additionally, HIV-1 and CMV specific IL-17 producing CD4 T cells are detectable in early 
HIV-1 infection, but are undetectable in chronic and non-progressive HIV-1 infection (Yue, 
Merchant et al., 2008). These experiments together suggest that IL-17 producing T cells are 
associated with viral load and disease progression. They also call into question of what 
impact the restoration of Th17 cells would have on the progression of HIV in the long run. If 
reconstitution is possible, increased Th17 levels may be beneficial in slowing the progression 
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of the disease towards AIDS, in particular with regard to the function of these cells to 
control possible fungal, parasitic, and bacterial opportunistic infections. 
It is unclear if Th17 cells are preferentially targeted by HIV for infection. One study 
suggested preferential targeting of CCR6+CCR5+ Th17 cells by CCR5 tropic viruses in vivo 
(El Hed, Khaitan et al., 2010). CCR4+ CCR6+ and CXCR3+ CCR6+ T cells express cytokines 
and transcription factors specific for Th17 and Th1/Th17 lineages respectively. These 
markers contribute to gut and lymph node homing potential. These two types of cells are 
highly permissive to HIV replication in that while their frequency is diminished, they can 
recruit more CCR6+ T cells into sites of viral replication (Gosselin, Monteiro et al., 2010). 
Similarly, in SIV infection, ǂ4ǃ7hiCD4 memory T cells were found to harbour most Th17 
cells and were significantly depleted (Kader, Wang et al., 2009). In SIV infected macaques, 
one group found that Th17 loss at mucosal surfaces predicted AIDS progression 
(Cecchinato, Trindade et al., 2008). Furthermore, there was a negative correlation between 
Th17 cell frequencies at mucosal sites and plasma virus level. Altogether these papers found 
that Th17 cells were preferentially depleted within a few weeks in HIV/SIV infection. Other 
reports show that Th17 cells may not be preferentially infected by HIV in vivo. Rather, CD4 
T cell development was shown to be skewed away from the Th17 phenotype toward Th1 
cell maturation in HIV patients (Brenchley, Paiardini et al., 2008) possibly leading to a 
significant loss of Th17 cells in the GI tract of HIV patients.  
Although there is ample evidence to state that Th17 is important in HIV pathogenesis, it is 
still unclear how Th17 cells and IL-17 are regulated during HIV infection. Understanding 
how Th17 cells are dysregulated by HIV infection is crucial to restoring its population and 
function and it is possible that treatments designed to increase Th17 levels may be beneficial 
to HIV infection. This may be particularly important in the protection against opportunistic 
diseases, given that Th17 cells have been well characterized to protect against bacterial, 
parasitic, and fungal infections. 
6. Treg in HIV infection 
Treg cells function to prevent chronic immune activation and act in a suppressive manner to 
control immune activation. These cells are generally defined phenotypically as CD4, CD25+, 
and Foxp3+. It appears that within the setting of HIV infection, the Treg CD4 T cell population 
may be protective to the host by potentially suppressing HIV infection in conventional CD4 T 
cells as well as cytotoxic T cell activity (Moreno-Fernandez, Rueda et al., 2011;Kinter, McNally 
et al., 2007). The Treg population has been demonstrated to coordinate and maintain virus-
specific immune responses (Rouse, Sarangi et al., 2006). Although Tregs have been shown to 
be infected by HIV, this may depend on the strain as well as host and viral properties. Moreno-
Fernandez and colleagues (2009) demonstrated that X4 viruses exhibited a higher level of 
infection in Tregs at early time points compared to R5 viruses in Tregs and X4 viruses in 
effector T cells (Moreno-Fernandez, Zapata et al., 2009). A study which examined viral 
persistence in Treg cells found that these cells are preferentially targeted by HIV, as a greater 
number of Treg cells harboured more HIV DNA than non-Treg cells (Tran, de Goer de Herve 
MG et al., 2008). Of interest, the Foxp3 Treg transcription factor has been shown to enhance 
HIV gene expression via an NF-B dependent mechanism(Holmes, Knudsen et al., 2007). 
Additionally, HIV-specific Treg cells have been detected (Kared, Lelievre et al., 2008;Torheim, 
Ndhlovu et al., 2009). Indeed, HIV has been shown to bind to Treg cells via gp120/CD4 
interactions which has been correlated with increased suppressive activities, extended Treg 
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survival, and upregulated homing receptors for peripheral lymph nodes and mucosal 
lymphoid tissues (Ji & Cloyd, 2009;Nilsson, Boasso et al., 2006). In the same study, it was 
shown that these Treg cells did not exhibit the same homing-induced apoptosis. Taken 
together, this suggests that the HIV-Treg interaction may contribute to upregulated levels of 
Tregs observed in lymphoid and mucosal compartments in HIV positive patients (Mozos, 
Garrido et al., 2007; Ji & Cloyd, 2009; Nilsson, Boasso et al., 2006).  
Absolute numbers of Treg and Treg frequency during HIV infection is an area of contention 
in this field. However, it has been demonstrated that the relative frequency of Treg cells 
within the CD4 T cell population as a whole appears to increase during HIV infection while 
at the same time, the absolute numbers of Tregs decline(Schulze Zur, Thomssen et al., 2011). 
This is supported by several studies which indicated a gradual decline in Treg absolute 
numbers during HIV pathogenesis (Jiao, Fu et al., 2009; Prendergast, Prado et al., 2010; 
Thorborn, Pomeroy et al., 2010; Cao, Jamieson et al., 2009). In particular, in primary HIV 
infection in untreated individuals, HIV-specific Treg cells and suppressive activity 
decreased over a 24 month follow-up period (Kared, Lelievre et al., 2008). Interestingly, a 
recent study by Weis et al. (2010) demonstrated that Treg cells were able to control immune 
activation in patients on ART, however this control was lost during interruption of ART, an 
observation attributed to the decline in absolute Treg numbers(Weiss, Piketty et al., 2010).  
Immune activation during HIV infection has been linked to HIV progression and negative 
outcomes during HIV infection (Douek, 2003; Kassiotis & O'Garra, 2008; Lawn, Butera et al., 
2001; Terzieva, 2008). Tregs could be protective as they can control this immune 
hyperactivation especially during chronic infection (Fazekas de St & Landay, 2008; Belkaid 
& Rouse, 2005). On the other hand, excess Treg activity results in “over” suppression of 
immune responses resulting in too much immune suppression, leading to faster HIV 
progression and negative outcomes (Kinter, Horak et al., 2007). This point is also supported 
by a report showing that recombinant IL-2 treatment in a phase III trial actually enhanced 
Treg populations, possibly explaining why this treatment failed to elicit better clinical 
outcome (Weiss, Letimier et al., 2010). Treg depletion has been associated with an increase in 
immune activation (Eggena, Barugahare et al., 2005) and several important studies have 
demonstrated correlation of Treg proliferation and turnover with lower CD4 counts (Bi, 
Suzuki et al., 2009; Piconi, Trabattoni et al., 2010; Xing, Fu et al., 2010).  
Interestingly, elite controllers, a rare population of individuals that can maintain 
undetectable HIV viral loads in the absence of HAART, demonstrated higher frequencies of 
Treg cells compared to individuals on HAART (Chase, Yang et al., 2008). On the other hand, 
Owen et al., showed that individuals on HAART had higher frequencies of Tregs compared 
to elite controllers (Owen, Heitman et al., 2010). In contrast yet again, more recent studies 
have demonstrated that elite controllers have a lower level of Treg cells compared to viremic 
individuals, but that this “low” level of Tregs is similar to that observed in HIV positive 
individuals with viral load controlled by HAART (Brandt, Benfield et al., 2011). In support 
of this, another group demonstrated that elite controllers had an even lower Treg frequency 
than HIV negative individuals (Hunt, Landay et al., 2011). In view of these studies it seems 
that the Treg frequency in elite controllers may vary according to the patient group 
examined and to which group the comparison is being made.  
7. Th17 versus Treg in HIV infection 
Since the main function of Th17 is to mediate inflammatory responses, and it is involved in 
autoimmune diseases, it is prudent that the response is kept under control to avoid damage 
www.intechopen.com
 
HIV-Host Interactions 
 
194 
to host tissue. Treg development is inexorably associated with Th17 development. IL-2, an 
important growth factor for T cells, is one of several cytokines that mediates the balance 
between Th17 and Tregs. In vitro, levels of Th17 were reduced in the presence of IL-2, while 
Treg numbers increased with IL-2 stimulation (Stockinger, 2007). The same is true with 
respect to HIV infection; a recent study demonstrated that administration of IL-2 to HIV 
patients on ART resulted in enhanced levels of CD4 T cells and Treg cells (Ndhlovu, Sinclair 
et al., 2010b). Overall enhancement of the CD4 T cell count was attributed to enhanced levels 
of naïve T cells. At the same time, this resulted in a decrease in Th17 cell frequency, 
although the absolute numbers of Th17 did not change. These results suggest then that IL-2 
is important for driving the differentiation of CD4 T cells and is selective for Treg 
development while not affecting levels of Th17 cells already present.  
As mentioned before, TGF-ǃ function straddles the border between Treg and Th17 
differentiation depending on the presence of IL-6. It is suggested that TGF-ǃ is constitutively 
produced by the resting immune system to induce Tregs to limit the effect of activated 
memory T cells (Korn, Bettelli, Oukka, & Kuchroo, 2009). However, in the event that the 
immune system is triggered, IL-6 is induced to inhibit the production of Tregs and cause a 
switch towards Th17 development (Korn, Bettelli, Oukka, & Kuchroo, 2009). This supports 
the claim that both TGF-ǃ and IL-6 must be present for Th17 differentiation. The parallel use 
of TGF-ǃ in both Treg and Th17 subsets may be important in mediating the balance between 
the two. It has been suggested that Th17 and Treg share a reciprocal relationship (Bettelli, 
Carrier et al, 2006; Mucida, Park et al., 2007; Zhou, Lopes et al., 2008; Quintana, Basso et al., 
2008). It has been shown that the observed rapid Th17 decline in acute HIV infection is 
predictive of the immune activation later seen in chronic infection. These studies also 
observed a loss of the Th17/Treg balance in pathogenic SIV infection (Lederer, Favre et al., 
2009). More recently, Prendergast et al (2010) demonstrated a profound loss of Th17 cells 
before advanced disease, in contrast to a gradual decline of Treg cells (Prendergast, Prado et 
al,, 2010). In a recent review, B. Kanwar et al. suggest that it is the relative balance of these 
two subsets of T cells that is key to the regulation of progression of HIV/AIDS, as opposed 
to considering only the specific functions of either subset alone(Kanwar, Favre et al., 2010). 
Future work in this regard will be key to furthering our understanding of the impact of this 
virus on our immune system. 
8. The “other” subsets: Th2, Th9, Tfh 
As discussed above, clearly HIV infection impacts the function of Th1, Th17, and Treg cells. 
The antibody response supported by the Th2 T cell subset is critically important to anti-HIV 
immune responses, however the scope of this topic fell outside the realm of this chapter. 
Currently little is known about the impact of HIV infection on the development and 
function of Th9 and Tfh cells. It is interesting to speculate that the differentiation 
programming and functional effects of these cells are disrupted during infection and 
warrant further research in this regard. 
9. Conclusion 
In Figure 2, the overall effect of HIV infection on Th cell subset is illustrated. In actuality, it 
is likely that the mechanisms and impact of the virus on these cells is much more complex 
than portrayed here, however this diagram summarizes the general outcome of CD4 T cell 
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differentiation in terms of Th1, Treg, and Th17 cells during HIV infection. Our immune 
systems consist of many complex processes that are interconnected and the effect of 
inhibiting or upregulating particular cell types will affect not only that particular cell type, 
but a multitude of other cells and cellular processes. As we further our understanding of 
HIV infection and HAART on the regulation of the differentiation of the CD4 T cell 
response, this will enhance our ability to design new treatment therapeutics and potential 
vaccine targets. 
 
Fig. 2. Impact of HIV infection on the IL-12 family of cytokines and their respective effects 
on CD4 T cell development. Shown are the T helper (Th) subsets discussed in detail in this 
chapter. Cytokines that induce their differentiation are shown preceding the cell type, and 
effector cytokines are listed below each cell type. Dark arrows indicate well-defined 
increases (up arrow) or decreases (down arrows) in cytokines (IL-12) or Th cells (Th17 and 
Treg). Large arrows with question marks indicate increases (up arrows) or decreases (down 
arrow) in cytokine and receptor expression that are not well defined. Shown in the top left is 
the ability of IL-27 to inhibit HIV replication.   
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